Company battles patent cliff with aggressive obesity strategy while oncology wins provide momentum for potential rebound
Pfizer shares are trading in the mid-$20s as investors grapple with a critical question: is this battered pharmaceutical giant destined to remain stuck in neutral, or does its aggressive push into obesity drugs and oncology successes position the company for a surprising rebound? The answer may hinge on three major obesity-related deals that could reshape Pfizer’s future beyond its looming patent challenges.
The obesity strategy takes shape
Pfizer has made aggressive moves to catch up in the rapidly expanding weight loss drug market after its own internal programs failed. The company discontinued two oral GLP-1 candidates, lotiglipron in 2023 and danuglipron in 2025, due to liver safety concerns. These setbacks left Pfizer without a viable in-house obesity pill just as competitors were making billions from weight loss medications.
The pharmaceutical giant responded by shifting from building its own drugs to acquiring and licensing promising candidates from other companies. This pivot represents one of the most significant strategic changes in Pfizer’s recent history, with billions of dollars committed to buying back into a market where rivals already dominate.
Deal number one: Metsera acquisition
Pfizer completed its acquisition of Metsera in November 2025 for $65.60 per share in cash, representing an enterprise value of approximately $7 billion plus contingent payments tied to development milestones. Some reports valued the total deal at up to $10 billion when including all potential milestone payments.
The acquisition brought several clinical-stage obesity and cardiometabolic candidates into Pfizer’s portfolio. The most advanced asset, MET-097i, is a weekly and monthly injectable GLP-1 receptor agonist preparing to enter Phase 3 development. The company also gained MET-233i, a monthly amylin analog currently in Phase 1 testing both alone and in combination with other drugs, plus an oral GLP-1 receptor agonist in Phase 1 and additional preclinical programs.
The less-frequent dosing schedule of MET-097i compared to existing weekly injections could provide a competitive advantage if the drug proves effective and safe. Patients often struggle with adherence to chronic medications, making convenience a crucial factor in the obesity market where treatment typically continues indefinitely.
Deal number two: YaoPharma licensing agreement
On December 9, Pfizer announced an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, for YP05002. This small-molecule GLP-1 receptor agonist is currently in Phase 1 development for chronic weight management.
The financial terms included $150 million upfront, up to $1.94 billion in milestone payments and tiered royalties if the drug receives approval. YaoPharma will complete the ongoing clinical trial while Pfizer gains rights to develop, manufacture and commercialize the drug globally.
Two strategic elements make this deal particularly interesting. First, Pfizer negotiated an opt-out clause allowing it to cancel with 60 days written notice, reflecting the uncertainty inherent in early-stage metabolic programs. Second, the agreement represents part of a broader industry trend where multinational pharmaceutical companies increasingly license China-developed GLP-1 assets to accelerate timelines and diversify their pipelines.
The appeal of an oral pill versus an injection is significant. Pills offer more convenience than injections, potentially improving patient adherence to long-term treatment. However, existing oral versions have faced challenges including absorption constraints and complex dosing requirements. Successfully developing an easy-to-take, scalable pill could unlock enormous market potential as obesity treatment becomes recognized as requiring lifelong management similar to other chronic conditions.
Deal number three: Flagship partnership expansion
The newest development came Monday with the announcement of a research program under Pfizer’s strategic partnership with Flagship Pioneering and Repertoire Immune Medicines. The collaboration aims to identify and optimize T-cell receptor bispecifics for metastatic prostate cancer, representing the eighth program launched under Flagship’s broader alliance with Pfizer that began in 2023.
While this program won’t generate near-term revenue, it demonstrates Pfizer’s commitment to rebuilding its oncology pipeline with next-generation immunotherapy approaches. The company’s core challenge isn’t insufficient research spending but rather investor confidence that this spending will produce differentiated drugs capable of replacing revenue lost to patent expirations.
The patent cliff looms large
Pfizer faces a major loss-of-exclusivity cycle that provides the gravitational force behind its deal-making spree and cost-cutting programs. Key products including Eliquis, Xtandi, Ibrance and Prevnar 13 are expected to lose patent protection by 2028. These medications represented a significant portion of Pfizer’s revenue base before generic competition begins eroding sales.
The company guided for 2026 revenue between $59.5 billion and $62.5 billion, essentially flat compared to 2025. Management expects roughly $1.5 billion in year-over-year revenue headwinds from declining COVID product sales and another $1.5 billion from loss-of-exclusivity effects. Meanwhile, research and development spending will increase to between $10.5 billion and $11.5 billion to advance major clinical programs.
Pfizer explicitly told investors to expect bumpy years before returning to growth, with management pointing to acquisitions and pipeline progress as the bridge to 2029 and 2030. This acknowledgment of near-term weakness makes the obesity and oncology strategies even more critical for the company’s future.
Oncology provides momentum
While obesity captures headlines, Pfizer has been stacking tangible wins in cancer treatment that help support the turnaround narrative. On December 17, Pfizer and Astellas announced positive results from an interim analysis of the Phase 3 EV-304 trial studying PADCEV plus Keytruda in muscle-invasive bladder cancer.
The study met its primary endpoint with statistically significant improvement in event-free survival and also achieved a key secondary endpoint in overall survival. Pfizer positioned the regimen as the first and only perioperative treatment without platinum-based chemotherapy to improve both metrics in cisplatin-eligible patients. The companies plan to discuss these results with regulators for potential filing submissions.
Additional late-stage trial results showed Tukysa added to maintenance therapy delayed disease progression in HER2-positive metastatic breast cancer patients who had already responded to initial treatment. Data presented at the San Antonio Breast Cancer Symposium demonstrated meaningful progression-free survival improvement when the drug was combined with Herceptin and Perjeta for maintenance.
These oncology wins matter because they demonstrate repeatable execution in a therapeutic area where Pfizer has placed major strategic bets. Positive Phase 3 readouts that expand addressable patient populations represent exactly the kind of pipeline progress investors want to see as the company works to offset patent-related revenue losses.
Racing against established competitors
Pfizer’s challenge extends beyond developing successful drugs to doing so while competitors continue advancing their own pipelines. Novo Nordisk filed for FDA approval of CagriSema, a next-generation obesity injection combining semaglutide with an amylin-pathway candidate, with regulatory review expected in 2026. Eli Lilly’s oral GLP-1 drug orforglipron has shown supportive trial results and generated strong sales expectations from analysts.
By the time Pfizer’s newly acquired and licensed obesity drugs produce meaningful clinical data, the standard of care may have evolved substantially. This reality explains why Pfizer adopted a portfolio approach, pursuing both injectables and oral medications, GLP-1 and non-GLP-1 mechanisms, and combining internal development with external licensing to create multiple opportunities for success.
SOURCE: TECHSTOCK2
Disclaimer: This article is for informational purposes only and does not constitute financial advice. The author and publication are not registered investment advisors and do not provide personalized investment recommendations.